{
    "pmcid": "7483421",
    "qa_pairs": {
        "How were the humanized single domain antibodies selected for their ability to bind the SARS-CoV-2 RBD?": [
            "Through four rounds of biopanning using a phage display library",
            "By direct binding assays with purified RBD protein",
            "Using computational docking simulations",
            "Via in vivo selection in transgenic mice"
        ],
        "What enhancement was made to the sdAbs to improve their therapeutic potential?": [
            "Fusion with the human IgG1 Fc domain",
            "Addition of a polyethylene glycol (PEG) moiety",
            "Conjugation with a fluorescent dye",
            "Attachment of a lipid tail for membrane anchoring"
        ],
        "What future direction did the study suggest for further optimizing the sdAbs?": [
            "Conducting structural analysis of sdAb-RBD complexes",
            "Performing high-throughput screening of additional sdAb variants",
            "Developing sdAbs against bacterial pathogens",
            "Testing sdAbs in human clinical trials immediately"
        ],
        "What was the primary target of the humanized single domain antibodies developed in the study?": [
            "The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein",
            "The nucleocapsid protein of SARS-CoV-2",
            "The membrane protein of SARS-CoV-2",
            "The envelope protein of SARS-CoV-2"
        ],
        "What was the range of equilibrium dissociation constants (KD) for the selected sdAbs binding to the SARS-CoV-2 RBD?": [
            "0.99 to 35.5 nM",
            "0.01 to 0.5 nM",
            "10 to 100 nM",
            "50 to 150 nM"
        ]
    }
}